182 related articles for article (PubMed ID: 28207808)
1. Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes.
Lacoste S; Bhatia S; Chen Y; Bhatia R; O'Connor TR
PLoS One; 2017; 12(2):e0171473. PubMed ID: 28207808
[TBL] [Abstract][Full Text] [Related]
2. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
Chakraborty S; Sun CL; Francisco L; Sabado M; Li L; Chang KL; Forman S; Bhatia S; Bhatia R
J Clin Oncol; 2009 Feb; 27(5):791-8. PubMed ID: 19124806
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
[TBL] [Abstract][Full Text] [Related]
4. Granulocytes affect double-strand break repair assays in primary human lymphocytes.
Lacoste S; Bhatia R; Bhatia S; O'Connor TR
PLoS One; 2014; 9(3):e93185. PubMed ID: 24667872
[TBL] [Abstract][Full Text] [Related]
5. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
6. DNA Repair Capacity for Personalizing Risk and Treatment Response - Assay Development and Optimization in Human Peripheral Blood Mononuclear Cells (PBMCs).
Nasrallah NA; Zhou H; Smith PA; Sears CR
DNA Repair (Amst); 2022 Mar; 111():103274. PubMed ID: 35085879
[TBL] [Abstract][Full Text] [Related]
7. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
8. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
9. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related myelodysplasia and acute myeloid leukemia.
Bhatia S
Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
[TBL] [Abstract][Full Text] [Related]
11. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.
Hahn T; McCarthy PL; Carreras J; Zhang MJ; Lazarus HM; Laport GG; Montoto S; Hari PN
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1740-4. PubMed ID: 24096096
[TBL] [Abstract][Full Text] [Related]
12. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
[TBL] [Abstract][Full Text] [Related]
13. Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma.
Procházka V; Gawande RS; Cayci Z; Froelich JW; Cao Q; Wilke C; Dusenbery K; Weisdorf DJ; Bachanova V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):64-70. PubMed ID: 28942016
[TBL] [Abstract][Full Text] [Related]
14. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
[TBL] [Abstract][Full Text] [Related]
15. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
Maziarz RT; Wang Z; Zhang MJ; Bolwell BJ; Chen AI; Fenske TS; Freytes CO; Gale RP; Gibson J; Hayes-Lattin BM; Holmberg L; Inwards DJ; Isola LM; Khoury HJ; Lewis VA; Maharaj D; Munker R; Phillips GL; Rizzieri DA; Rowlings PA; Saber W; Satwani P; Waller EK; Maloney DG; Montoto S; Laport GG; Vose JM; Lazarus HM; Hari PN
Br J Haematol; 2013 Sep; 162(5):648-56. PubMed ID: 23829536
[TBL] [Abstract][Full Text] [Related]
16. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
[TBL] [Abstract][Full Text] [Related]
17. Functional DNA repair system analysis in haematopoietic progenitor cells using host cell reactivation.
Thoms KM; Baesecke J; Emmert B; Hermann J; Roedling T; Laspe P; Leibeling D; Truemper L; Emmert S
Scand J Clin Lab Invest; 2007; 67(6):580-8. PubMed ID: 17852814
[TBL] [Abstract][Full Text] [Related]
18. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
[TBL] [Abstract][Full Text] [Related]
19. NMR-based metabolomic analysis of the molecular pathogenesis of therapy-related myelodysplasia/acute myeloid leukemia.
Cano KE; Li L; Bhatia S; Bhatia R; Forman SJ; Chen Y
J Proteome Res; 2011 Jun; 10(6):2873-81. PubMed ID: 21510650
[TBL] [Abstract][Full Text] [Related]
20. Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years.
Martínez C; Jorge AS; Pereira A; Moreno M; Núñez J; Gayoso J; Gonzalez-Medina J; Revilla N; Sampol A; Domingo-Domenech E; de la Cruz F; Morales A; Rodriguez-Salazar MJ; Valiente S; Pérez-Ceballos E; de Oteyza JP; García-Sanz R;
Ann Hematol; 2017 Jan; 96(1):9-16. PubMed ID: 27752822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
